Q-omics provides the consensus-scored GALK1 profile across patient tissues and cancer cell-line models. GALK1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GALK1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, GALK1 protein abundance shows 21,094 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, COAD, and PDAC as cancer lineages where GALK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALK1 survival associations across molecular data types. GALK1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALK1 RNA expression–survival associations across cancer types. High GALK1 expression shows unfavorable associations in BLCA, UVM, ACC, KIRC, MESO and KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GALK1 RNA expression.
This table summarizes GALK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GALK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALK1 shows lower tumor expression in KICH and higher tumor expression in COAD, BLCA, THCA, BRCA and UCEC. The COAD box plot shows higher GALK1 RNA expression in tumor versus normal tissue (log2 FC = +1.815, t-test p < 0.001).
This table shows molecular features associated with GALK1 in patient tissues and cancer cell lines. In patient samples, GALK1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GALK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
